Home LiteratureArticle Details
PMID: 15957152 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.

The Journal of pathology ·Vol. 207 ·No. 1 ·2005-09-00 ·Pages 1-13

Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Valgeirsson H, Lambros M, Ashworth A, Palacios J, Schmitt F, Lakhani SR

Abstract

Immunohistochemical analysis of E-cadherin has changed the way lobular neoplasia is perceived. It has helped to classify difficult cases of carcinoma in situ with indeterminate features and led to the identification of new variants of lobular carcinoma. Pleomorphic lobular carcinoma (PLC) and pleomorphic lobular carcinoma in situ (PLCIS), recently described variants of invasive and in situ classic lobular carcinoma, are reported to be associated with more aggressive clinical behaviour. Although PLC/PLCIS show morphological features of classic lobular neoplasia and lack E-cadherin expression, it is still unclear whether these lesions evolve through the same genetic pathway as lobular carcinomas or are high-grade ductal neoplasms that have lost E-cadherin. Here we have analysed a case of extensive PLCIS and invasive PLC associated with areas of E-cadherin-negative carcinoma in situ with indeterminate features, using immunohistochemistry, chromogenic in situ hybridization, high-resolution comparative genomic hybridization (CGH) and array-based CGH. We observed that all lesions lacked E-cadherin and beta-catenin and showed gain of 1q and loss of 16q, features that are typical of lobular carcinomas but are not seen in high-grade ductal lesions. In addition, amplifications of c-myc and HER2 were detected in the pleomorphic components, which may account for the high-grade features in this case and the reported aggressive clinical behaviour of these lesions. Taken together, these data suggest that at least some PLCs may evolve from the same precursor or through the same genetic pathway as classic lobular carcinomas.

MeSH Terms
Adult Biomarkers, Tumor/metabolism Breast Neoplasms/genetics,metabolism,pathology Cadherins/metabolism Carcinoma in Situ/genetics,metabolism,pathology Carcinoma, Lobular/genetics,metabolism,pathology Chromosome Aberrations Cytoskeletal Proteins/metabolism DNA, Neoplasm/genetics Female Humans Immunoenzyme Techniques In Situ Hybridization/methods Microdissection/methods Neoplasm Invasiveness Neoplasm Proteins/metabolism Nucleic Acid Hybridization Oligonucleotide Array Sequence Analysis/methods Trans-Activators/metabolism beta Catenin
Chemicals
Biomarkers, Tumor CTNNB1 protein, human Cadherins Cytoskeletal Proteins DNA, Neoplasm Neoplasm Proteins Trans-Activators beta Catenin
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Reis-Filho Jorge S
The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK. jorgerf@icr.ac.uk
Simpson Pete T
Jones Chris
Steele Dawn
Mackay Alan
Iravani Marjan
Fenwick Kerry
Valgeirsson Haukur
Lambros Maryou
Ashworth Alan
Palacios Jose
Schmitt Fernando
Lakhani Sunil R
Article Info
Journal
The Journal of pathology
Abbr.
J Pathol
ISSN
0022-3417
Published
2005-09-00
Pages
1-13
Language
English
Region
England
NLM ID
0204634
Subset
IM
Grants
Breast Cancer Now · BREAST CANCER NOW RESEARCH CENTRE · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com